ABCAM PLC Vesting of All Employee Share Scheme
06 November 2021 - 02:19AM
RNS Non-Regulatory
TIDMABC
ABCAM PLC
05 November 2021
ABCAM PLC
Vesting of 'AbShare', Abcam's All Employee Share Scheme
5 November 2021, Cambridge, UK - Abcam plc ("Abcam" or "the
Company") (AIM LSE: ABC; Nasdaq: ABCM), is delighted to announce
that the performance conditions have been met for AbShare, the
Group's all employee share scheme launched in 2018, and all awards
will vest in full on Monday 8 November.
The scheme will see approximately 1.8 million shares awarded to
over 1,350 employees (excluding the Executive Directors) who
elected to participate in the plan, which has won multiple awards,
including being voted the most innovative and creative share plan
by the Global Equity Awards in 2019.
Shares under the AbShare plan were awarded at GBP12.19 a share,
the prevailing price in November 2018. This compares with the
closing price as of 4 November 2021 of GBP16.91.
Commenting on the news, Nick Skinner, SVP of HR, said:
"AbShare was launched in 2018 with the goal of fostering greater
employee ownership across our entire global worksforce. I am
delighted that as that programme vests, approximately 90% of our
global team are now shareholders in the Company."
--- Ends ---
Abcam plc
+44 (0) 1223 696 000
James Staveley, VP Investor Relations
Marc Perkins, Company Secretary
Numis - Nominated Advisor & Joint Corporate Broker
+ 44 (0) 20 7260 1000
Garry Levin / Freddie Barnfield / Duncan Monteith
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
antibodies, assays and other research tools to address important
targets in critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health.
Abcam's worldwide customer base of approximately 750,000 life
science researchers uses Abcam's antibodies, reagents, biomarkers
and assays. By actively listening to and collaborating with these
researchers, the Company continuously advances its portfolio to
address their needs. A transparent programme of customer reviews
and datasheets, combined with an industry-leading validation
initiative, gives researchers increased confidence in their
results.
Founded in 1998 and headquartered in Cambridge, UK, the Company
has served customers in more than 130 countries. Abcam's ordinary
shares are listed on the London Stock Exchange (AIM: ABC) and its
American Depositary Shares (ADSs) trade on the Nasdaq Global Market
(Nasdaq: ABCM).
For more information, please visit corporate.abcam.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEELFBFFLFFBQ
(END) Dow Jones Newswires
November 05, 2021 11:19 ET (15:19 GMT)
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Mar 2023 to Mar 2024